Thought leadership
EMP-01: Developing novel treatments for social anxiety disorder
Thought leadership
Addressing the unmet need in treatment-resistant depression
Media
Safer Psychedelic Drugs May Be Coming
Media
MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD
Media
How the next psychedelics companies believe they can avoid Lykos’ fate
Media
Atai’s DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant